Valeant Pharmaceuticals said Friday that the Food and Drug Administration approved its Luzu cream, which is designed to treat fungal infections. The Canadian drugmaker said Luzu, or luliconazole, is intended to treat athlete's foot, jock itch, and ringworm. It said the cream is indicated for...
Valeant Pharmaceuticals lost $973 million in the third quarter, due to a $645 million...
Valeant Pharmaceuticals will pay Anacor Pharmaceuticals $142.5 million in a settlement, the...
Valeant Pharmaceuticals turned a second-quarter profit, as acquisitions and sales from emerging markets helped to counter a jump in some expenses. The Canadian company also raised its 2013 earnings forecast. Valeant earned $10.9 million, or 3 cents per share, in the three months that ended June 30.
Valeant said Monday that it will eliminate as much as 15 percent of its workforce and move Bausch & Lomb's headquarters to New Jersey as part of its $8.7 billion acquisition of the company.In a letter to its own and Bausch & Lomb workers, Valeant said that after the deal closes, it will eliminate between 10 percent and 15 percent of positions companywide. That works out to between 1,850 and 2,775 people.
Canadian drugmaker Valeant Pharmaceuticals International Inc. said Monday it will sell $1.75 billion in stock to help fund its acquisition of Bausch + Lomb. Valeant did not say how many shares it plans to sell. The company said it plans to raise $1.75 billion before discounts, expenses, and other...
Analysts raised their earnings estimates for Valeant Pharmaceuticals International Inc. Wednesday after the Canadian drug developer agreed to buy Bausch + Lomb in a major expansion of its ophthalmology business. THE OPINION: Jefferies & Co. analyst Corey Davis described the deal as "extremely...
Canadian drugmaker Valeant Pharmaceuticals says it will buy eye-health company Bausch + Lomb for $8.7 billion in cash in a massive expansion of its ophthalmology business. Valeant says the deal will help it capitalize on increasing demand for contact lenses and other products because of aging...
Valeant Pharmaceuticals Announces Resignation of Dr. Laurence Paul from Valeant's Board of DirectorsMay 16, 2013 7:56 am | News | Comments
Valeant Pharmaceuticals International, Inc. announced that Dr. Laurence Paul has resigned from Valeant's Board of Directors due to expanded business, philanthropic, and personal commitments. Dr. Paul was originally elected to Biovail Corporation's Board of Directors in June 2002 where he served in several capacities.
Actavis Inc. said Wednesday it acquired a bacterial vaginosis gel developed by Valeant Pharmaceuticals International Inc. Actavis said it agreed to pay Valeant $55 million for its metronidazole gel product, which has not yet received marketing approval. The total includes both an upfront payment...
Actavis and Valeant Pharmaceuticals today announced that Actavis has reached settlement agreements with Medicis Pharmaceutical Corporation, a subsidiary of Valeant, resolving outstanding patent litigation related to Actavis' Abbreviated New Drug Application for Clindamycin and Tretinoin Gel, a generic version of Ziana, as well as Actavis' ANDA for Imiquimod Cream, a generic version of Zyclara.
German drugmaker Merz Pharma Group has ended a plan to acquire Obagi Medical Products Inc. after a competitor raised its bid to buy the dermatology products maker. Merz said Monday it is a "disciplined buyer," and it was withdrawing its $22-per-share cash bid for Obagi after Canadian drugmaker Valeant Pharmaceuticals raised its offer last week to $24 per share.
Valeant Pharmaceuticals International Inc. said Thursday that a newly approved generic version of one of its drugs could significantly reduce its profits this year. Mylan Inc. on Wednesday received final approval from the U.S. Food and Drug Administration to sell the first generic version of...
Valeant Pharmaceuticals International, Inc. today announced that Valeant and Obagi Medical Products, Inc. have executed an amendment to their Agreement and Plan of Merger, dated March 19, 2013. Pursuant to the amendment, Valeant increased its offer to acquire Obagi from $19.75 to $24.00 per share in cash.
German drugmaker Merz Pharma Group said Tuesday that it wants to buy dermatology products maker Obagi for about $383.5 million, toping an offer made by Canada's Valeant Pharmaceuticals last month. Merz said it sent a letter to Obagi Medical Products Inc.'s board offering to buy all of the company's stock for $22 per share.
Valeant Pharmaceuticals International, Inc. today announced that it has entered into a definitive agreement under which Valeant will acquire all of the outstanding common stock of Obagi Medical Products, Inc. for $19.75 per share in cash, which represents a 28% premium to Obagi's closing share price on March 19, 2013, the last trading day prior to announcement.
Valeant Pharmaceuticals International Inc. reported a fourth-quarter loss, as acquisition-related costs countered steep revenue growth for the Canadian drugmaker. Valeant focuses on dermatology, neurology and branded generics. Its products include the antidepressant Wellbutrin XL and the blood...
Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., and Valeant Pharmaceuticals International, Inc. announced today that Valeant has acquired U.S. rights for Targretin (bexarotene) capsules and Targretin (bexarotene) gel 1% from Eisai for $65 million upfront, plus potential contingent payments based on certain milestones
Valeant Pharmaceuticals International, Inc. has reached agreement on terms of a revised North American aesthetics arrangement with Galderma S.A.
Valeant Pharmaceuticals International, Inc. announced today that Ryan Weldon and Jason Hanson will be named to Valeant's Executive Management Team.
Valeant Pharmaceuticals has announced that Rajiv De Silva, Valeant's President and Chief Operating Officer of Specialty Pharmaceuticals, will be leaving the company to pursue other interests.
Valeant Pharmaceuticals International, Inc. announced today that Valeant has agreed to acquire OraPharma, a specialty oral health company that develops and commercializes products that improve and maintain oral health, from Water Street Healthcare Partners.
MONTREAL — Valeant Pharmaceuticals International Inc. expects to grow in emerging and niche markets that aren't being eyed by "big pharma," chief executive officer Michael Pearson said Wednesday.
Valeant Pharmaceuticals International, Inc. announced today that it has agreed to acquire certain assets from Swiss Herbal Remedies Limited, a nutraceutical company that manufactures and markets a broad range of scientifically formulated vitamins, minerals and supplements, for less than one times sales.
Valeant Pharmaceuticals International, Inc. announced today that Valeant has signed an agreement to acquire certain assets from Atlantis Pharma, a branded generics pharmaceutical company located in Mexico with a broad product portfolio, including products in the gastro, analgesics and anti-inflammatory therapeutic categories, for approximately $71 million.
Valeant Pharmaceuticals International, Inc. announced today that the company has acquired Pedinol Pharmacal, Inc., a podiatry-focused, privately-owned specialty pharmaceutical company based in the U.S., for less than 1.5 times sales.
Valeant Pharmaceuticals International Inc. said Tuesday that it is buying a generic aspirin and other products from Austrian generic drugmaker Gerot Lannach as part of a push to expand in Eastern Europe.
Valeant Pharmaceuticals International, Inc. announced today that the company has acquired a 19.9% minority equity investment in Pele Nova Biotecnologia S.A. a Brazilian research company focused on tissue regeneration.
- Page 1